Chronic liver injury results in hepatic fibrosis, which is characterized by extensive deposition of extracellular matrix proteins (ECM), increased levels of TGF- 1 and circulating endotoxin (lipopolysaccharide, LPS), and activation of collagen producing myofibroblasts. Development of liver fibrosis is accompanied by recruitment of bone marrow (BM)-derived fibrocytes, that are CD45 and collagen-a1(I) expressing cells, previously implicated in the pathogenesis of fibrosis in lungs, skin, and kidneys. We have demonstrated that fibrocytes contribute to liver fibrosis by comprising 4-6% of collagen producing cells in the fibrotic liver and differentiating into fibrogenic myofibroblasts. Despite of low numbers, our preliminary data suggest that inhibition of fibrocyte function(s) by the natural inhibitor Serum Amyloid P (SAP), results in the blockage of fibrocyte flux into fibrotic liver, and significantly attenuates liver fibrosis. Current proposal investigates the effect of SAP on liver fibrosis, fibrocyte recruitment and differentiation into myofibroblasts, and mediation of inflammatory signals in the course of liver fibrosis using two models of liver injury, carbontetrachloride (CCl4 and bile duct ligation (BDL). We anticipate that fibrocytes play an important role in pathogenesis of liver fibrosis (AIM 1). Therefore, fibrocytes may present an attractive target for anti-fibrotictherapy. To support our hypothesis, we developed a complimentary approach to study the role of fibrocytes in liver fibrosis. Using Cre-loxP recombination technique, we generate transgenic mice devoid of fibrocytes (AIM 2). Ablation of fibrocytes in vivo is achieved by overexpression of Diphtheria toxin-a (DTA) or receptor (DTR) in Collagen-a1(I)+CD45+ fibrocytes. Deletion of fibrocytes has not been reported, and will provide the invaluable insight into the role of fibrocytes in pathogenesis of liver fibrosis. We believe that fibrocytes may become a novel target for anti-fibrotic therapy. Futhermore, fibrocyte inhibitor SAP, which is used in clinical trals for lung and skin fibrosis, may present a potentially new treatment for patients with liver fibrosi. Here we determine the origin of BM-derived fibrocytes (hematopoietic or mesenchymal), and define their relationship to common myeloid progenitors (CMP) and monocytes (AIM 3). We predict that fibrocytes originate from c-kit+Sca-1+ hematopoietic stem cells, but developmentally precede CMP during hematopoiesis. In concordance, fibrocytes possess high plasticity, and in response to liver injury migrate to fibrotic liver, but also to spleen where they mediate antimicrobial response. It remains unclear how expression of collagen affects functions of fibrocytes. We address this question by generation of collagen-mutant fibrocytes, which downregulate collagen-a1(I) production (5'SL), or express a more stable uncleavable Col1a1rr protein (AIM 4). The functions of mutant fibrocytes are studied in vivo and compared to the wild type fibrocytes. We expect that mutant collagen-deficient fibrocytes exhibit a defect in transmigration, differentiation into myofibroblasts, while Col1a1rr-mutant fibrocytes are expected to possess a highly fibrogenic phenotype.

Public Health Relevance

Hepatic fibrosis and its end stage, cirrhosis, represent an enormous health care burden worldwide. The goal of this study is to determine the role of bone marrow-derived fibrocytes, designated as Collagen Type I expressing hematopoietic cells, in the pathogenesis of liver fibrosis. Further understanding of fibrocyte biology (mechanism of migration, cellular origin, and contribution to fibrogenesis and inflammation) can make these cells an attractive target for anti-fibrotic therapy.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
High Priority, Short Term Project Award (R56)
Project #
Application #
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Doo, Edward
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
Internal Medicine/Medicine
Schools of Medicine
La Jolla
United States
Zip Code
Ma, Hsiao-Yen; Xu, Jun; Liu, Xiao et al. (2016) The role of IL-17 signaling in regulation of the liver-brain axis and intestinal permeability in Alcoholic Liver Disease. Curr Pathobiol Rep 4:27-35
Karin, Daniel; Koyama, Yukinori; Brenner, David et al. (2016) The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis. Differentiation 92:84-92
Xu, Jun; Kisseleva, Tatiana (2015) Bone marrow-derived fibrocytes contribute to liver fibrosis. Exp Biol Med (Maywood) 240:691-700
Xu, Jun; Liu, Xiao; Gao, Bin et al. (2014) New Approaches for Studying Alcoholic Liver Disease. Curr Pathobiol Rep 2:171-183
Iwaisako, Keiko; Jiang, Chunyan; Zhang, Mingjun et al. (2014) Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci U S A 111:E3297-305
Liu, Xiao; Xu, Jun; Brenner, David A et al. (2013) Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts. Curr Pathobiol Rep 1:209-214